【摘要】 目的 通過meta分析評(píng)價(jià)多聯(lián)預(yù)康復(fù)在食管癌患者術(shù)后恢復(fù)中的應(yīng)用效果。方法 檢索PubMed、Embase、Cochrane Library、Web of Science、中國(guó)知網(wǎng)、萬(wàn)方、維普、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)中關(guān)于多聯(lián)預(yù)康復(fù)應(yīng)用于食管癌患者的隨機(jī)對(duì)照試驗(yàn),檢索范圍設(shè)定從建庫(kù)起至2023年10月1日,納入文獻(xiàn)在質(zhì)量學(xué)評(píng)價(jià)后,用RevMan 5.4軟件進(jìn)行meta分析。結(jié)果 納入10篇文獻(xiàn)共930例患者,meta分析結(jié)果顯示,多聯(lián)預(yù)康復(fù)相對(duì)于常規(guī)護(hù)理可降低食管癌患者術(shù)后并發(fā)癥發(fā)生率[相對(duì)危險(xiǎn)度(RR)=0.62,95%CI 0.47~0.82],縮短住院時(shí)間[均數(shù)差(MD)=-6.15 d,
95%CI -7.87~-4.43 d]及降低住院費(fèi)用(MD=-1.78萬(wàn)元,95%CI -2.76萬(wàn)元~-0.81萬(wàn)元),增加術(shù)后6分鐘步行距離(MD=93.35 m,95%CI 36.19~150.51 m),提高術(shù)后血清白蛋白含量(MD=6.18 g/L,95%CI 4.08~8.28 g/L)和免疫球蛋白(Ig)G含量[標(biāo)準(zhǔn)化均數(shù)差(SMD)=1.21,95%CI 1.01~1.42]。結(jié)論 多聯(lián)預(yù)康復(fù)有利于食管癌患者術(shù)后恢復(fù),降低術(shù)后并發(fā)癥發(fā)生率,改善部分運(yùn)動(dòng)、營(yíng)養(yǎng)和免疫功能指標(biāo),縮短住院時(shí)間且減少住院費(fèi)用。
【關(guān)鍵詞】 食管癌;多聯(lián)預(yù)康復(fù);術(shù)后恢復(fù);干預(yù)效果;隨機(jī)對(duì)照試驗(yàn);meta分析
Effectiveness of multimodal prehabilitation in patients with esophageal neoplasm: a meta-analysis of RCTs
WANG Jianhua1, ZHANG Wangjian2, HUANG Sijia3, LIU Li3
(1.Health Statistics Association of Guangdong Province, Guangzhou 510060, China; 2.School of Public Health, Sun Yat-sen University, Guangzhou 510080, China; 3.Department of Nursing,Sun Yat-sen University Cancer Center, Guangzhou 510062, China)
Corresponding author: LIU Li, E-mail: liuli@sysucc.org.cn
【Abstract】 Objective To evaluate the effectiveness of multimodal prehabilitation among patients with esophageal neoplasm through meta-analysis. Methods Randomized controlled trials (RCTs) reporting the effectiveness of multimodal prehabilitation in patients with esophageal neoplasm were searched from PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, Chongqing VIP and CBM databases from the inception to October 1, 2023. Meta-analysis was performed by RevMan 5.4 software after quality evaluation. Results Ten RCTs consisting of 930 patients were included in this meta-analysis. The meta-analysis results showed that compared with conventional nursing, multimodal prehabilitation could lower the incidence of postoperative complications (relative risk (RR) =0.62, 95%CI 0.47-0.82), and shorten the length of hospital stay (mean difference (MD) =-6.15 d, 95%CI -7.87--4.43 d),
reduce hospital costs (MD=CNY-17 800, 95%CI -27 600--8 100), prolong 6-minute walking distance (MD=93.35 m, 95%CI 36.19-150.51 m) and increase serum albumin levels (MD=6.18 g/L, 95%CI 4.08-8.28 g/L) and IgG levels (standardized mean difference (SMD)=1.21, 95%CI 1.01-1.42), respectively. Conclusions Multimodal prehabilitation can accelerate postoperative recovery, decrease the incidence of postoperative complications, improve partial exercise, nutritional and immunological indexes, shorten the length of hospital stay and reduce hospitalization costs.
【Key words】 Esophageal neoplasm; Multimodal prehabilitation; Postoperative recovery; Interventional effect;
Randomized controlled trial; Meta-analysis
食管癌致死率較高,病情進(jìn)展后可引發(fā)多種繼發(fā)癥并危及生命,我國(guó)是食管癌疾病負(fù)擔(dān)最重的國(guó)家之一[1]。手術(shù)是早中期食管癌的首選方案[2],但術(shù)后常見肺部感染等并發(fā)癥[3],且可出現(xiàn)運(yùn)動(dòng)能力下降、免疫功能低下等術(shù)后恢復(fù)問題[4],對(duì)患者生活質(zhì)量造成不利影響。多聯(lián)預(yù)康復(fù)是一種康復(fù)管理新策略,指通過對(duì)患者術(shù)前實(shí)施2種或以上預(yù)康復(fù)措施,包括運(yùn)動(dòng)訓(xùn)練、營(yíng)養(yǎng)支持、心理干預(yù)及健康教育等[5],增強(qiáng)患者對(duì)后續(xù)治療的耐受力,有助于患者術(shù)后較快恢復(fù)。多聯(lián)預(yù)康復(fù)研究日漸受到重視,學(xué)者們探索多聯(lián)預(yù)康復(fù)對(duì)食管癌患者干預(yù)效果,但研究結(jié)果存在差異。有研究表明多聯(lián)預(yù)康復(fù)可降低食管癌患者術(shù)后并發(fā)癥發(fā)生率[6-7]、減少住院時(shí)間[6-8]、改善營(yíng)養(yǎng)指標(biāo)[9-11]、提高運(yùn)動(dòng)能力[12];但部分研究則顯示,多聯(lián)預(yù)康復(fù)相對(duì)常規(guī)護(hù)理對(duì)并發(fā)癥發(fā)生率[13-14]、住院時(shí)間[15]等干預(yù)效果差異無(wú)統(tǒng)計(jì)學(xué)意義。本研究擬通過meta分析系統(tǒng)評(píng)價(jià)食管癌患者術(shù)前多聯(lián)預(yù)康復(fù)對(duì)術(shù)后恢復(fù)的影響,提供較全面的臨床實(shí)踐依據(jù)。
1 對(duì)象與方法
1.1 文獻(xiàn)納入和排除標(biāo)準(zhǔn)
納入標(biāo)準(zhǔn):①研究對(duì)象是確診早中期食管癌的患者,年齡≥18歲,進(jìn)行或完成食管癌手術(shù)治療;②隨機(jī)對(duì)照試驗(yàn)(randomized controlled trial,RCT);③試驗(yàn)組采用多聯(lián)預(yù)康復(fù),對(duì)照組采用常規(guī)護(hù)理;④結(jié)局指標(biāo)包括術(shù)后并發(fā)癥發(fā)生率、住院時(shí)間、住院費(fèi)用、6分鐘步行距離(6-minute walking distance,6MWD)、術(shù)后血清白蛋白、術(shù)后免疫球蛋白(Ig)G;⑤中文或英文文獻(xiàn)。排除標(biāo)準(zhǔn):①只有計(jì)劃但尚未開始的研究;②判斷為重復(fù)發(fā)表的文獻(xiàn);③無(wú)法取得全文或數(shù)據(jù)。
研究主題已經(jīng)在PROSPERO平臺(tái)注冊(cè)fV/tK8BFcaHNP6OAats4Rw==,編號(hào)CRD42023471507。
1.2 數(shù)據(jù)庫(kù)檢索策略
檢索PubMed、Embase、Cochrane Library、Web
of Science、中國(guó)知網(wǎng)、維普數(shù)據(jù)庫(kù)、萬(wàn)方數(shù)據(jù)庫(kù)、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù),結(jié)合使用主題詞加自由詞。中文檢索采用“食管癌/食道癌/食管腫瘤/賁門癌”“預(yù)康復(fù)/康復(fù)訓(xùn)練”“術(shù)前鍛煉/快速康復(fù)/
早期營(yíng)養(yǎng)/術(shù)前心理”;英文檢索采用“esophageal
neoplasms/esophageal cancer/esophageal surgery”“gastric cardia cancer/cardia cancer”“prehabilitation/rehabilitation/early nutrition/early exercise/early psychology”。檢索時(shí)限為建庫(kù)至2023年10月1日。通過滾雪球方式繼續(xù)檢索參考文獻(xiàn),補(bǔ)充符合條件的文獻(xiàn)。以PubMed為例,使用檢索策略如下:
#1 esophageal neoplasms[Mesh Terms]
#2 esophageal cancer OR esophageal surgery
[Title/Abstract]
#3 gastric cardia cancer OR cardia cancer[Title/Abstract]
#4 #1 OR #2 OR #3
#5 rehabilitation[Mesh Terms]
#6 prehabilitation[Title/Abstract]
#7 #5 OR #6
#8 *nutrition OR *exercise OR *psychology
#9 #4 AND #7 AND #8
1.3 文獻(xiàn)篩選及資料獲得
由3名具有循證醫(yī)學(xué)能力的研究者共同開展本研究。其中2名研究者按標(biāo)準(zhǔn)獨(dú)立對(duì)數(shù)據(jù)庫(kù)進(jìn)行檢索、初篩和篩選符合標(biāo)準(zhǔn)的文獻(xiàn),出現(xiàn)意見分歧時(shí)進(jìn)行協(xié)商,可向第3名研究者咨詢后做出決定。需要收集如下信息:①文獻(xiàn)作者和發(fā)表時(shí)間等基礎(chǔ)信息;②試驗(yàn)組和對(duì)照組樣本量等數(shù)據(jù)資料;③預(yù)康復(fù)方案及測(cè)量時(shí)間等內(nèi)容;④擬研究的各種結(jié)局指標(biāo)。
1.4 文獻(xiàn)質(zhì)量評(píng)價(jià)
質(zhì)量評(píng)價(jià)的標(biāo)準(zhǔn)來(lái)自Cochrane 5.1.0手冊(cè),2名研究者獨(dú)立操作,經(jīng)EndNote去重、閱讀題目、閱讀摘要、閱讀全文等步驟,篩選出最終納入的文獻(xiàn),對(duì)照標(biāo)準(zhǔn)進(jìn)行質(zhì)量評(píng)價(jià)。質(zhì)量評(píng)價(jià)含7個(gè)項(xiàng)目,每個(gè)項(xiàng)目有低風(fēng)險(xiǎn)、高風(fēng)險(xiǎn)和不清楚3個(gè)選項(xiàng),如全部為低風(fēng)險(xiǎn),等級(jí)為A級(jí),部分為低風(fēng)險(xiǎn),等級(jí)為B級(jí),全部非低風(fēng)險(xiǎn)則等級(jí)為C級(jí)。質(zhì)量評(píng)價(jià)工作同樣由第3名研究者進(jìn)行分歧裁決。
1.5 統(tǒng)計(jì)學(xué)方法
Meta分析使用RevMan 5.4軟件。用相對(duì)危險(xiǎn)度(risk ratio,RR)作為計(jì)數(shù)資料的效應(yīng)指標(biāo),用均數(shù)差(mean difference,MD)或標(biāo)準(zhǔn)化均數(shù)差(standardized mean difference,SMD)作為計(jì)量資料的效應(yīng)指標(biāo)。對(duì)納入研究用檢驗(yàn)聯(lián)合I2 值來(lái)判定異質(zhì)性,P > 0.10且I2 < 50%提示異質(zhì)性不顯著,優(yōu)選固定效應(yīng)模型;當(dāng)P≤0.10、I2 ≥50%則表明異質(zhì)性明顯,選隨機(jī)效應(yīng)模型[16]。采用漏斗圖進(jìn)行發(fā)表偏倚分析。
2 結(jié) 果
2.1 文獻(xiàn)檢索
從各數(shù)據(jù)庫(kù)共獲取779篇文獻(xiàn),從其他資源補(bǔ)充獲得5篇相關(guān)文獻(xiàn),最終納入10篇文獻(xiàn),見圖1。
2.2 納入文獻(xiàn)的基本特征和方法學(xué)質(zhì)量評(píng)價(jià)
在納入研究的10篇文獻(xiàn)[6-15]中,有2篇英文和8篇中文。采用多聯(lián)預(yù)康復(fù)的試驗(yàn)組467例,采用常規(guī)護(hù)理的對(duì)照組463例,共930例食管癌患者。各研究的多聯(lián)預(yù)康復(fù)方案不完全統(tǒng)一,在文獻(xiàn)中有具體描述,并提供結(jié)局指標(biāo)相關(guān)數(shù)據(jù)。納入文獻(xiàn)的基本特征見表1。文獻(xiàn)質(zhì)量評(píng)價(jià)結(jié)果中,質(zhì)量等級(jí)A級(jí)1篇[12],B級(jí)9篇[6-11, 13-15],見表2。
2.3 Meta分析結(jié)果
結(jié)果顯示術(shù)后并發(fā)癥發(fā)生率、術(shù)后6MWD、住院時(shí)間、住院費(fèi)用、術(shù)后血清白蛋白、術(shù)后IgG等6項(xiàng)指標(biāo),差異均具有統(tǒng)計(jì)學(xué)意義(P均< 0.05),見表3。
2.3.1 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者術(shù)后并發(fā)癥的影響
6篇文獻(xiàn)[6-7, 12-15]報(bào)告了多聯(lián)預(yù)康復(fù)對(duì)食管癌患者術(shù)后并發(fā)癥發(fā)生率的影響,異質(zhì)性不顯著(P = 0.32,I2 = 14%),故用固定效應(yīng)模型分析,發(fā)現(xiàn)試驗(yàn)組可降低并發(fā)癥發(fā)生率,2組對(duì)比有統(tǒng)計(jì)學(xué)差異(RR = 0.62,95%CI 0.47~0.82),見圖2。
2.3.2 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者步行距離的影響
術(shù)后6MWD可反映食管癌患者的術(shù)后運(yùn)動(dòng)能力,有4項(xiàng)研究[6, 10, 12, 14]報(bào)告了此結(jié)局指標(biāo),結(jié)果具有異質(zhì)性(P < 0.001,I2 = 94%),故用隨機(jī)效應(yīng)模型分析,試驗(yàn)組的6MWD高于對(duì)照組,2組有統(tǒng)計(jì)學(xué)差異(MD = 93.35 m,95%CI 36.19~150.51 m),見圖3。
2.3.3 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者住院時(shí)間的影響
6項(xiàng)研究[6-8, 10, 12, 14-15]報(bào)告了食管癌患者住院時(shí)間,結(jié)果具有異質(zhì)性(P = 0.07,I2 = 50%),采用隨機(jī)效應(yīng)模型分析,發(fā)現(xiàn)試驗(yàn)組比對(duì)照組住院時(shí)間縮短,2組有統(tǒng)計(jì)學(xué)差異(MD = -6.15 d,95%CI -7.87~-4.43 d),見圖4。
2.3.4 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者住院費(fèi)用的影響
4項(xiàng)研究[6-8, 14]報(bào)告了食管癌患者住院費(fèi)用,結(jié)果具有異質(zhì)性(P < 0.001,I2 = 95%),故用隨機(jī)效應(yīng)模型分析,發(fā)現(xiàn)對(duì)照組術(shù)后住院費(fèi)用高于對(duì)照組,2組有統(tǒng)計(jì)學(xué)差異(MD = -1.78萬(wàn)元,95%CI -2.76萬(wàn)元~-0.81萬(wàn)元),見圖5。
2.3.5 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者術(shù)后血清白蛋白的影響
5項(xiàng)研究[6, 8-11]報(bào)告了食管癌患者術(shù)后血清白蛋白,結(jié)果具有異質(zhì)性(P < 0.001,I2 = 89%),故用隨機(jī)效應(yīng)模型分析,發(fā)現(xiàn)試驗(yàn)組術(shù)后血清白蛋白高于對(duì)照組,2組有統(tǒng)計(jì)學(xué)差異(MD = 6.18 g/L,95%CI 4.08~8.28 g/L),見圖6。
2.3.6 多聯(lián)預(yù)康復(fù)對(duì)食管癌患者術(shù)后IgG的影響
3項(xiàng)研究[8, 11, 13]報(bào)告了食管癌患者術(shù)后IgG,異質(zhì)性不顯著(P = 0.93,I2 = 0%),故用固定效應(yīng)模型分析,發(fā)現(xiàn)試驗(yàn)組的術(shù)后IgG高于對(duì)照組,2組有統(tǒng)計(jì)學(xué)差異(SMD = 1.21,95%CI 1.01~1.42),見圖7。
2.4 發(fā)表偏倚分析
對(duì)上述各指標(biāo)做漏斗圖進(jìn)行偏倚檢驗(yàn),結(jié)果顯示各指標(biāo)的漏斗圖體現(xiàn)了較好的對(duì)稱性,未發(fā)現(xiàn)明顯的發(fā)表偏倚,見圖8。
3 討 論
食管癌手術(shù)是外科領(lǐng)域創(chuàng)傷大、具挑戰(zhàn)性的手術(shù)之一,術(shù)后恢復(fù)慢,術(shù)后并發(fā)癥發(fā)生率和病死率較高,尤以肺部并發(fā)癥為顯著[17-18]。雖然預(yù)后風(fēng)險(xiǎn)不可避免,但是本研究通過meta分析顯示多聯(lián)預(yù)康復(fù)可降低肺不張、肺炎、切口感染和吻合口瘺等術(shù)后并發(fā)癥的發(fā)生率,在提高手術(shù)成功率、加速術(shù)后恢復(fù)和提高患者生活質(zhì)量方面發(fā)揮積極作用,有助于推動(dòng)食管癌治療模式從傳統(tǒng)的“治療疾病”向“關(guān)注患者整體健康”轉(zhuǎn)變。
預(yù)康復(fù)是基于術(shù)后快速康復(fù)治療理念的一種術(shù)前管理新策略。既往研究表明,癌癥患者往往伴有營(yíng)養(yǎng)不良、肌力下降、焦慮抑郁和其他身心不佳的情況,預(yù)康復(fù)可通過干預(yù)措施改善上述癥狀,增強(qiáng)患者對(duì)后續(xù)輔助治療的耐受力,從而促進(jìn)患者的康復(fù),在臨床各外科領(lǐng)域均得到廣泛的應(yīng)用[19-20]。多聯(lián)預(yù)康復(fù)相對(duì)于單一康復(fù)方式,要求不同學(xué)科之間相互協(xié)作,康復(fù)效果的優(yōu)勢(shì)得以明顯提升。本研究納入的10篇文獻(xiàn)均同時(shí)實(shí)施了運(yùn)動(dòng)訓(xùn)練、營(yíng)養(yǎng)支持和心理干預(yù)3種主要預(yù)康復(fù)訓(xùn)練,部分研究還輔以藥物康復(fù)或其他輔助方法。不同康復(fù)訓(xùn)練的干預(yù)頻率和時(shí)長(zhǎng)未完全統(tǒng)一,通常認(rèn)為,心理干預(yù)可在入院后盡早開始,運(yùn)動(dòng)訓(xùn)練需確定患者安全的前提下制定具體方案,營(yíng)養(yǎng)支持則根據(jù)患者情況制定個(gè)性化方案。
術(shù)后并發(fā)癥可能會(huì)讓患者出現(xiàn)病情反彈或惡化,導(dǎo)致住院時(shí)間更長(zhǎng)、住院費(fèi)用更高[21-23],是食管癌患者術(shù)后面臨的重要問題。本研究結(jié)果表明,多聯(lián)預(yù)康復(fù)可通過降低并發(fā)癥發(fā)生率,促進(jìn)患者快速康復(fù),縮短住院時(shí)間,減少住院費(fèi)用。入院即進(jìn)行預(yù)康復(fù)方案評(píng)估,多學(xué)科協(xié)作并給予患者聯(lián)合方案干預(yù),包括適當(dāng)?shù)臓I(yíng)養(yǎng)支持、必要的運(yùn)動(dòng)訓(xùn)練和針對(duì)性的心理干預(yù),均能幫助患者達(dá)到更良好的身心狀態(tài),提高患者手術(shù)時(shí)的體能和耐力。護(hù)理人員或康復(fù)人員通過健康教育,可以提高食管癌患者及家屬對(duì)多聯(lián)預(yù)康復(fù)的知信行,使其更好地配合,達(dá)成干預(yù)目的?;颊叩目焖倏祻?fù)和心理情緒恢復(fù)有利于其較快達(dá)到出院標(biāo)準(zhǔn),縮短住院時(shí)間且減少住院費(fèi)用[24]。食管癌患者的多聯(lián)預(yù)康復(fù)有利于及時(shí)釋放床位資源,減輕醫(yī)院負(fù)荷,提高醫(yī)療效率,促進(jìn)醫(yī)療資源的合理分配,給醫(yī)療系統(tǒng)和社會(huì)帶來(lái)積極影響。
采用循序漸進(jìn)的運(yùn)動(dòng)訓(xùn)練是多聯(lián)預(yù)康復(fù)的關(guān)鍵措施之一,考慮患者病情,通常建議以快走或慢跑等有氧運(yùn)動(dòng)為主,結(jié)合適當(dāng)?shù)臒o(wú)氧運(yùn)動(dòng)。本研究結(jié)果顯示,多聯(lián)預(yù)康復(fù)可明顯改善食管癌患者術(shù)后6MWD,原因可能是運(yùn)動(dòng)訓(xùn)練具有改善機(jī)體適應(yīng)能力的效果,可以提高患者的呼吸換氣效率,降低氧耗,通過鍛煉上下肢的肌群增加呼吸肌的力量,切實(shí)提升機(jī)體肌肉功能和運(yùn)動(dòng)能力[25]。預(yù)康復(fù)運(yùn)動(dòng)訓(xùn)練的呼吸鍛煉還起到增強(qiáng)肺功能和肺活量,促進(jìn)排痰和通氣,預(yù)防肺不張等并發(fā)癥的作用,進(jìn)而加速了食管癌患者術(shù)后恢復(fù)。
多聯(lián)預(yù)康復(fù)可改善患者手術(shù)前的機(jī)體整體狀況,幫助患者進(jìn)行生理儲(chǔ)備,達(dá)成較好的術(shù)前功能狀態(tài),能更好面對(duì)手術(shù)過程的應(yīng)激反應(yīng),從而有助于術(shù)后快速恢復(fù),調(diào)整到更佳的身心狀態(tài)[26]。本研究發(fā)現(xiàn),多聯(lián)預(yù)康復(fù)組的部分營(yíng)養(yǎng)和免疫功能相關(guān)指標(biāo)比對(duì)照組恢復(fù)更好,原因可能是在術(shù)前進(jìn)行早期干預(yù),予以較全面的運(yùn)動(dòng)訓(xùn)練、營(yíng)養(yǎng)支持、心理干預(yù)以及其他輔助干預(yù)手段,上述各方面可以起到正向作用又相互促進(jìn),有效增加患者術(shù)前的營(yíng)養(yǎng)和免疫物質(zhì)儲(chǔ)備,更好應(yīng)對(duì)術(shù)中和術(shù)后的代謝消耗,加速術(shù)后血清白蛋白和IgG的恢復(fù)[22]。
本研究采用meta分析方法對(duì)食管癌患者多聯(lián)預(yù)康復(fù)干預(yù)效果進(jìn)行綜合評(píng)價(jià),克服單篇論文樣本量較少的缺陷,進(jìn)而得出較明確的結(jié)論,為臨床護(hù)理決策提供有價(jià)值的參考,具有一定的創(chuàng)新性。10篇納入文獻(xiàn)的質(zhì)量評(píng)價(jià)之中,1篇A級(jí)和9篇B級(jí),部分文獻(xiàn)未說(shuō)明試驗(yàn)分配方案隱藏和實(shí)施盲法的具體情況,meta分析結(jié)果的穩(wěn)健性會(huì)受到納入研究質(zhì)量的影響。建議RCT研究重視質(zhì)量評(píng)價(jià)的7個(gè)方面,特別是分配方案隱藏和盲法實(shí)施等2項(xiàng)易忽視環(huán)節(jié)。本研究將繼續(xù)關(guān)注新進(jìn)展,有符合標(biāo)準(zhǔn)的文獻(xiàn)可納入更新。
本研究明確多聯(lián)預(yù)康復(fù)可降低食管癌患者術(shù)后并發(fā)癥發(fā)生率,縮短住院時(shí)間,降低住院費(fèi)用,增加術(shù)后6MWD,并提高血清白蛋白和IgG。但多聯(lián)預(yù)康復(fù)的最佳組合方式、干預(yù)時(shí)間和干預(yù)頻率,尚未統(tǒng)一。未來(lái)應(yīng)開展更多同類RCT,在高質(zhì)量和大樣本基礎(chǔ)上探討多聯(lián)預(yù)康復(fù)的具體方案,為食管癌多聯(lián)預(yù)康復(fù)提供更多的循證依據(jù)。
參 考 文 獻(xiàn)
[1] MALHOTRA G K, YANALA U, RAVIPATI A, et al. Global trends in esophageal cancer[J]. J Surg Oncol, 2017, 115(5): 564-579. DOI: 10.1002/jso.24592.
[2] MARTIN-RICHARD M, DíAZ BEVERIDGE R, ARRAZUBI V, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)[J]. Clin Transl Oncol, 2016, 18(12):
1179-1186. DOI: 10.1007/s12094-016-1577-y.
[3] 廖佳倩, 王國(guó)蓉, 鄧曉園, 等. 食管癌病人術(shù)后肺部感染危險(xiǎn)因素的meta分析[J]. 全科護(hù)理, 2022, 20(9): 1163-1167. DOI: 10.12104/j.issn.1674-4748.2022.09.003.
LIAO J Q, WANG G R, DENG X Y, et al. meta-analysis of risk factors for postoperative pulmonary infection in patients with esophageal cancer[J]. Chin Gen Pract Nurs, 2022, 20(9): 1163-1167. DOI: 10.12104/j.issn.1674-4748.2022.09.003.
[4] 李虎, 王華. 胸腔鏡與傳統(tǒng)開放手術(shù)對(duì)行食管癌根治術(shù)患者的臨床療效、并發(fā)癥及中遠(yuǎn)期生存率的影響[J]. 癌癥, 2020, 39(1): 45-50.
LI H, WANG H. Effects of thoracoscopic surgery and traditional open surgery on clinical efficacy, complications and long-term survival rate of patients undergoing radical resection of esophageal cancer[J]. Chin J Cancer, 2020, 39(1): 45-50.
[5] MOLENAAR C J L, MINNELLA E M, COCA-MARTINEZ M, et al. Effect of multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: the PREHAB Randomized Clinical Trial[J]. JAMA Surg, 2023, 158(6): 572-581. DOI: 10.1001/jamasurg.2023.0198.
[6] 王鑫. 三聯(lián)預(yù)康復(fù)策略對(duì)食管癌術(shù)后患者結(jié)局及短期生活質(zhì)量的影響[D]. 呼和浩特: 內(nèi)蒙古醫(yī)科大學(xué), 2021. DOI: 10.27231/d.cnki.gnmyc.2021.000471.
WAND X. The effect of triple prehabilitation strategy on the outcome andshort-term quality of life of patients with esophageal cancer surgery[D]. Hohhot: Inner Mongolia Medical University, 2021. DOI: 10.27231/d.cnki.gnmyc.2021.000471.
[7] 郭仲, 冀賽光, 徐楊, 等. 術(shù)前預(yù)康復(fù)對(duì)食管癌病人術(shù)后營(yíng)養(yǎng)狀況與人體體成分的影響[J]. 腸外與腸內(nèi)營(yíng)養(yǎng), 2018, 25(3): 156-160. DOI: 10.16151/j.1007-810x.2018.03.008.
GUO Z, JI S G, XU Y, et al. The effect of preoperative prehabilitation on nutritional status and body composition of patients with esophageal cancer after operation[J]. Parenter Enter Nutr, 2018, 25(3): 156-160. DOI: 10.16151/j.1007-810x.2018.03.008.
[8] 謝琪, 王強(qiáng), 雷敏, 等. 術(shù)前預(yù)康復(fù)對(duì)食管癌患者術(shù)后營(yíng)養(yǎng)指標(biāo)、 人體體成分、 血糖、 炎癥反應(yīng)和免疫功能的影響[J]. 臨床誤診誤治, 2019, 32(12): 87-93. DOI: 10.3969/j.issn.
1002-3429.2019.12.019.
XIE Q, WANG Q, LEI M, et al. Effect of preoperative prehabilitation on nutritional indicators, body composition, blood glucose, inflammatory response and immune function of patients with esophageal cancer after operation[J]. Clin Misdiagnosis Mistherapy, 2019, 32(12): 87-93. DOI: 10.3969/j.issn.1002-3429.2019.12.019.
[9] 趙曉菊, 李雙蘭, 宋艷敏. 早期多維度康復(fù)護(hù)理對(duì)食管癌患者負(fù)性情緒及生活能力的影響[J]. 承德醫(yī)學(xué)院學(xué)報(bào), 2023, 40(4): 317-320. DOI: 10.15921/j.cnki.cyxb.2023.04.016.
ZHAO X J, LI S L, SONG Y M. Effect of early multidimensional rehabilitation nursing on negative emotions and living ability of patients with esophageal cancer[J]. J Chengde Med Univ, 2023, 40(4): 317-320. DOI: 10.15921/j.cnki.cyxb.2023.04.016.
[10] 葉秀珍, 王蘭, 章新亞. 基于多學(xué)科協(xié)作院前預(yù)康復(fù)策略在食管癌患者中的應(yīng)用[J]. 浙江臨床醫(yī)學(xué), 2023, 25(3): 438-439, 442.
YE X Z, WANG L, ZHANG X Y. Application of pre-hospital rehabilitation strategy based on multidisciplinary cooperation in patients with esophageal cancer[J]. Zhejiang Clin Med J, 2023, 25(3): 438-439, 442.
[11] 李紅晨, 童鋒, 應(yīng)佑華, 等. 預(yù)康復(fù)概念在食管癌患者圍手術(shù)期中的應(yīng)用[J]. 浙江醫(yī)學(xué), 2019, 41(12): 1301-1304. DOI: 10.12056/j.issn.1006-2785.2019.41.12.2017-1041.
LI H C, TONG F, YING Y H, et al. Prehabilitation program in perioperative period for patients with esophageal cancer[J]. Zhejiang Med J, 2019, 41(12): 1301-1304. DOI: 10.12056/j.issn.1006-2785.2019.41.12.2017-1041.
[12] MINNELLA E M, AWASTHI R, LOISELLE S E, et al. Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: a randomized clinical trial[J]. JAMA Surg, 2018, 153(12): 1081-1089. DOI: 10.1001/jamasurg.2018.1645.
[13] 肖楠, 劉媛媛, 唐華. 階段性營(yíng)養(yǎng)支持聯(lián)合術(shù)前預(yù)康復(fù)應(yīng)用于食管癌患者的效果觀察[J]. 中國(guó)療養(yǎng)醫(yī)學(xué), 2022, 31(7): 728-731. DOI: 10.13517/j.cnki.ccm.2022.07.016.
XIAO N, LIU Y Y, TANG H. Observation on the effect of staged nutritional support combined with preoperative pre-rehabilitation in patients with esophageal cancer[J]. Chin J Conval Med, 2022, 31(7): 728-731. DOI: 10.13517/j.cnki.ccm.2022.07.016.
[14] 董翠萍, 侯曉營(yíng), 潛艷, 等. “五聯(lián)” 預(yù)康復(fù)策略在高齡低肺功能食管癌術(shù)后病人護(hù)理中的應(yīng)用效果觀察[J]. 循證護(hù)理, 2020, 6(3): 264-269. DOI: 10.12102/j.issn.2095-8668.
2020.03.015.
DONG C P, HOU X Y, QIAN Y, et al. Effect observation on the “five-linked” prerehabilitation strategy in postoperative nursing of esopha-geal cancer patients with advanced age and low-level pulmonary function[J]. Chin Evid Based Nurs, 2020, 6(3): 264-269. DOI: 10.12102/j.issn.2095-8668.2020.03.015.
[15] ALLEN S K, BROWN V, WHITE D, et al. Multimodal prehabilitation during neoadjuvant therapy prior to esophagogastric cancer resection: effect on cardiopulmonary exercise test performance, muscle mass and quality of life-a pilot randomized clinical trial[J]. Ann Surg Oncol, 2022, 29(3): 1839-1850. DOI: 10.1245/s10434-021-11002-0.
[16] 張?zhí)灬? 傳統(tǒng)meta分析統(tǒng)計(jì)模型的合理使用[J]. 中國(guó)醫(yī)院統(tǒng)計(jì), 2023, 30(4): 299-303, 308. DOI: 10.3969/j.issn.1674-
4055.2020.07.01.
ZHANG T S. Rational use of statistical models for traditional meta-analysis[J]. Chin J Hosp Stat, 2023, 30(4): 299-303, 308. DOI: 10.3969/j.issn.1674-4055.2020.07.01.
[17] VAN EXTER S H, DRAGER L D, VAN ASSELDONK M, et al. Adherence to and efficacy of the nutritional intervention in multimodal prehabilitation in colorectal and esophageal cancer patients[J]. Nutrients, 2023, 15(9): 2133. DOI: 10.3390/nu15092133.
[18] GUINAN E M, DOWDS J, DONOHOE C, et al. The physiotherapist and the esophageal cancer patient: from prehabilitation to rehabilitation[J]. Dis Esophagus, 2017,
30 (1): 1-12. DOI: 10.1111/dote.12514.
[19] HALLIDAY L J, BOSHIER P R, DOGANAY E, et al. The effects of prehabilitation on body composition in patients undergoing multimodal therapy for esophageal cancer[J]. Dis Esophagus, 2023, 36(2): doac046. DOI: 10.1093/dote/doac046.
[20] CHRISTODOULIDIS G, HALLIDAY L J, SAMARA A, et al. Personalized prehabilitation improves tolerance to chemotherapy in patients with oesophageal cancer[J]. Curr Oncol, 2023,
30(2): 1538-1545. DOI: 10.3390/curroncol30020118.
[21] BAUSYS A, MAZEIKAITE M, BICKAITE K, et al. The role of prehabilitation in modern esophagogastric cancer surgery: a comprehensive review[J]. Cancers, 2022, 14(9): 2096. DOI: 10.3390/cancers14092096.
[22] 林杰, 錢佶, 蔣國(guó)軍, 等. 監(jiān)測(cè)外周血中性粒細(xì)胞胞外誘捕網(wǎng)含量對(duì)食管癌遠(yuǎn)處轉(zhuǎn)移的預(yù)測(cè)價(jià)值[J]. 新醫(yī)學(xué), 2022,
53 (10): 751-755. DOI: 10.3969/j.issn.0253-9802.2022.10.009.
LIN J, QIAN J, JIANG G J, et al. Value of neutrophil extracellular trap formation in predicting esophageal cancer distant metastasis[J]. J New Med, 2022, 53(10): 751-755. DOI: 10.3969/j.issn.0253-9802.2022.10.009.
[23] 陳蝶, 李雯, 吳司棋, 等. 早期經(jīng)口進(jìn)食對(duì)食管癌病人術(shù)后并發(fā)癥和康復(fù)療效影響的meta分析[J]. 全科護(hù)理, 2023, 21(1): 17-22. DOI: 10.12104/j.issn.1674-4748.2023.01.004.
CHEN D, LI W, WU S Q, et al. meta-analysis of the effects of early oral feeding on postoperative complications and rehabilitation of patients with esophageal cancer[J]. Chin Gen Pract Nurs, 2023, 21(1): 17-22. DOI: 10.12104/j.issn.
1674-4748.2023.01.004.
[24] 何賢英, 崔芳芳, 馬倩倩, 等. 河南省某三甲醫(yī)院食管癌超長(zhǎng)住院日患者分布特征分析[J]. 中國(guó)醫(yī)院統(tǒng)計(jì), 2023, 30(1):
48-51, 54. DOI: 10.3969/j.issn.1006-5253.2023.01.009.
HE X Y, CUI F F, MA Q Q, et al. Distribution characteristics of patients with esophageal cancer with over-long hospitalization days in a tertiary hospital in Henan Province[J]. Chin J Hosp Stat, 2023, 30(1): 48-51, 54. DOI: 10.3969/j.issn.1006-
5253.2023.01.009.
[25] 任子淇, 許勤, 張?zhí)熨Y. 預(yù)康復(fù)在癌癥患者中應(yīng)用的研究進(jìn)展[J]. 中國(guó)康復(fù)醫(yī)學(xué)雜志, 2019, 34(4): 487-490. DOI: 10.3969/j.issn.1001-1242.2019.04.024.
REN Z Q, XU Q, ZHANG T Z. Research progress on the application of pre-rehabilitation in cancer patients[J]. Chin J Rehabil Med, 2019, 34(4): 487-490. DOI: 10.3969/j.issn.
1001-1242.2019.04.024.
[26] BOLGER J C, LOUGHNEY L, TULLY R, et al. Perioperative prehabilitation and rehabilitation in esophagogastric malignancies: a systematic review[J]. Dis Esophagus, 2019, 32(9): doz058. DOI: 10.1093/dote/doz058.
(責(zé)任編輯:鄭巧蘭)